As I started seeking partners to help turn this concept into a reality, I knew we needed someone that was going to build the company alongside us and not just write a check. When I connected with Cure Ventures, they really dug deep into the science and came to truly understand both the risks and the possibilities. I knew that we were looking at this technology in the same way, which was a key driver of our decision to work with them. As we began working together, Cure got hands-on to help prioritize the experiments that advanced our science and navigate through the inevitable challenges that are inherent to early-stage biotech companies. You can’t control the science, but you can choose the people around you in the trenches. I can honestly say that Cure has been instrumental in keeping a level-head when the inevitable roadblocks have arisen and has put XenImmune in a position to have its best chance at success.
Aided by Cure Ventures’ diligent and rigorous approach to company building, we’re pioneering the platform technology of hyperacute rejection to fight cancer and I’m excited to say our lead therapy has shown proof-of-concept in in vitro and in vivo models. With the help of Cure’s seed funding and active collaboration, we continue to generate the data necessary to drive us forward as we seek Series A funding and advance our lead candidate further down the path to the clinic. In the future, I know Cure will be there to support us as we grow and reach new milestones. With Cure, we have more than an investor – they’re a true sweat equity partner working alongside the XenImmune team.